Tirzepatide costs between $900 and $1,400 per month without insurance coverage as of 2026. The average retail price is approximately $1,200 monthly for standard dosing. Insurance coverage significantly reduces costs, with most patients paying $25-100 monthly copays when covered. Pricing varies based on dosage strength, with 2.5mg starter doses costing around $900 monthly and higher maintenance doses of 10-15mg reaching $1,400. Manufacturer savings programs can reduce costs to $25-50 monthly for eligible patients. Compounded versions from telehealth providers range from $200-500 monthly, though these formulations differ from brand-name Mounjaro or Zepbound. Your final cost depends on insurance formulary placement, deductible status, and whether you qualify for patient assistance programs. Geographic location and pharmacy choice also influence pricing within this range.
Key Takeaways
- Monthly tirzepatide costs range from $900-1,400 without insurance in 2026
- Insurance coverage typically reduces costs to $25-100 monthly copays
- Manufacturer programs can lower costs to $25-50 for qualifying patients
- Compounded versions cost $200-500 monthly through telehealth providers
- Dosage strength directly affects monthly pricing
Brand-Name Tirzepatide Pricing Structure
Brand-name tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) follows a tiered pricing model based on dosage strength. The 2.5mg starting dose costs approximately $900 monthly, while the 5mg dose averages $1,050. Higher maintenance doses of 7.5mg cost around $1,200, 10mg reaches $1,300, and the maximum 15mg dose approaches $1,400 monthly. These prices reflect list prices before insurance or discount programs apply. Pharmacies may charge different dispensing fees, creating price variations of $50-100 between locations. Major chains like CVS and Walgreens typically align with manufacturer pricing, while independent pharmacies may offer slightly lower costs. Your prescribing physician's relationship with specific pharmacies can sometimes influence final pricing through professional discount agreements.Insurance Coverage and Copay Assistance
Most major insurance plans cover tirzepatide when prescribed for diabetes, resulting in monthly copays between $25-100. Weight loss indications receive less consistent coverage, with approximately 60% of commercial plans covering Zepbound as of 2026. Prior authorization requirements are common, requiring documentation of BMI over 30 or BMI over 27 with comorbidities. Eli Lilly's savings card program reduces costs to $25 monthly for commercially insured patients and $50 for those without insurance who meet income requirements. This program covers up to $150 in monthly savings, making it particularly valuable for patients with high deductible plans. Medicare and Medicaid patients cannot use manufacturer coupons but may qualify for separate patient assistance programs based on income verification. The growing popularity of peptide therapy has led some patients to explore alternative options. While traditional peptides like BPC-157 and TB-500 serve different therapeutic purposes, some patients investigate Sermorelin or Ipamorelin for metabolic benefits, though these compounds work through different mechanisms than GLP-1 receptor agonists.Compounded Tirzepatide Alternatives
Compounded tirzepatide from licensed pharmacies costs between $200-500 monthly, representing significant savings over brand-name versions. These formulations use the same active ingredient but may differ in excipients, concentration, or delivery method. Telehealth platforms often partner with compounding pharmacies to offer these alternatives, particularly for weight loss applications. Quality varies among compounding pharmacies, making verification of 503B outsourcing facility status important for safety. The FDA has issued guidance requiring compounders to demonstrate shortages of brand-name products before producing tirzepatide alternatives. Patients considering compounded versions should discuss efficacy monitoring with their healthcare provider, as dosing conversions between formulations may require adjustment.Frequently Asked Questions
Does insurance cover tirzepatide for weight loss?
Insurance coverage for weight loss varies significantly. Approximately 60% of commercial insurance plans cover Zepbound for obesity treatment as of 2026, typically requiring prior authorization and documentation of BMI over 30 or BMI over 27 with weight-related health conditions. Medicare Part D coverage is limited, and Medicaid coverage varies by state.
See transparent compounded pricing
Review compounded medication pricing and what provider-reviewed care includes, with no surprises at checkout.
Try the Cost Calculator →View data table
| Category | Relative Cost Index | Detail |
|---|---|---|
| Brand Ozempic | 95 | $900-1,350/mo without insurance |
| Brand Wegovy | 90 | $1,300-1,600/mo without insurance |
| Brand Mounjaro | 88 | $1,000-1,200/mo without insurance |
| Compounded | 25 | $299-449/mo at FormBlends |
How long do patients typically stay on tirzepatide?
Most patients require long-term treatment to maintain weight loss and glycemic benefits. Clinical studies show optimal results with continuous use, and discontinuation often leads to weight regain within 3-6 months. Budget planning should account for ongoing monthly costs, as tirzepatide is considered a chronic therapy rather than a short-term intervention.
Are there generic versions of tirzepatide available?
No generic versions of tirzepatide exist as of 2026. Eli Lilly holds patent protection through 2032, preventing generic competition. Compounded versions are available but differ from true generics in terms of FDA oversight and standardization. Biosimilar versions may emerge after patent expiration but require separate clinical trials for approval.
Can I use manufacturer coupons with government insurance?
Federal law prohibits manufacturer coupon use with Medicare, Medicaid, and other government insurance programs. However, Eli Lilly offers separate patient assistance programs for government insurance beneficiaries based on income qualification. These programs may provide medication at reduced cost or free of charge for eligible patients.
Sources
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 33667417
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024
- Eli Lilly and Company. Mounjaro (tirzepatide) prescribing information. 2022. Updated 2025.
- Centers for Medicare & Medicaid Services. Medicare Part D covered drugs. Accessed April 2026.
- American Diabetes Association. Standards of medical care in diabetes 2026. Diabetes Care. 2026;49(Suppl 1):S1-S321.
- FDA Center for Drug Evaluation and Research. Compounding and the FDA: Questions and answers. Updated March 2026.
- Academy of Managed Care Pharmacy. GLP-1 receptor agonist coverage trends 2026. J Manag Care Spec Pharm. 2026;32(4):412-420.
- National Association of Chain Drug Stores. Prescription drug pricing report 2026. Accessed April 2026.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →